The β-thalassemias

New England Journal of Medicine

Volumn 341, Issue 2, 1999, Pages 99-109

  Olivieri, Nancy F ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLOBIN; CHELATING AGENT; DEFERIPRONE; DEFEROXAMINE; HEMOGLOBIN; HEMOGLOBIN F;

AGRANULOCYTOSIS; ANEMIA; BETA THALASSEMIA; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; EMBRYOTOXICITY; GENE THERAPY; HEMOGLOBIN SYNTHESIS; HIGH RISK POPULATION; HUMAN; IRON CHELATION; IRON OVERLOAD; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; TERATOGENICITY;

BETA-THALASSEMIA; BONE MARROW TRANSPLANTATION; CHELATING AGENTS; CHROMOSOMES, HUMAN, PAIR 11; FETAL HEMOGLOBIN; GENE THERAPY; GENES; GLOBINS; HUMANS; IRON OVERLOAD; MUTATION; PHENOTYPE;

EID: 0033536288     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199907083410207     Document Type: Review

References (120)

1. Cooley TB, Lee P. A series of cases of splenomegaly in children with anemia and peculiar bone changes. Trans Am Pediatr Soc 1925;37:29-30.
2. Rietti F. Ittero emolitico primitivo. Alti Accad Sci Med Nat Ferrara 1925;2:14-9.
3. Greppi E. Ittero emolitico familiare con aumento della resistenza dei globuli. Minerva Med 1928;8:1-11.
4. Micheli P, Penati P, Momigliano LG. Ulteriori richereche sulla anemia ipocromica splenomegalica con poichilocitosi. Atti Soc Ital Ematol Haematol (Pavia) 1935;16:Suppl 1:10-3.
5. Whipple GH, Bradford WL. Mediterranean disease - thalassemia (erythroblastic anemia of Cooley): associated pigment abnormalities simulating hemochromatosis. J Pediatr 1936;9:279-311.
6. Weatherall DJ, Clegg JB. Thalassaemia - a global public health problem. Nat Med 1996;2:847-9.
7. Higgs DR. α-Thalassaemia. Baillieres Clin Haematol 1993;6:117-50.
8. Chui DH, Waye JS. Hydrops fetalis caused by alpha-thalassemia: an emerging health care problem. Blood 1998;91:2213-22.
9. Weatherall DJ. The thalassemias. In: Stamatoyannopoulos G, Nienhuis AW, Majerus PH, Varmus H, eds. The molecular basis of blood diseases. 2nd ed. Philadelphia: W.B. Saunders, 1994:157-205.
10. Flint J, Harding RM, Boyce AJ, Clegg JB. The population genetics of the haemoglobinopathies. Baillieres Clin Haematol 1993;6:215-62.
11. Weatherall DJ. Common genetic disorders of the red cell and the "malaria hypothesis." Ann Trop Med Parasitol 1987;81:539-48.
12. +-Thalassaemia protects children against disease caused by other infections as well as malaria. Proc Natl Acad Sci U S A 1997;94:14736-41.
13. Orkin SH. Regulation of globin gene expression in erythroid cells. Eur J Biochem 1995;231:271-81.
14. Wood WG, Weatherall DJ. Developmental genetics of the human haemoglobins. Biochem J 1983;215:1-10.
15. Wood WG. Increased HbF in adult life. Baillieres Clin Haematol 1993; 6:177-213.
16. Grosveld F, Dillon N, Higgs D. The regulation of human globin gene expression. Clin Haematol 1993;6:31-55.
17. Nathan DG, Gunn RB. Thalassemia: the consequences of unbalanced hemoglobin synthesis. Am J Med 1966;41:815-30.
18. Wickramasinghe SN. The morphology and kinetics of erythropoiesis in homozygous β-thalassaemia. In: Congenital disorders of erythropoiesis. Amsterdam: Elsevier, 1976:221-37.
19. Yuan J, Angelucci E, Lucarelli G, et al. Accelerated programmed cell death (apoptosis) in erythroid precursors of patients with severe beta-thalassemia. Blood 1993;82:374-7.
20. Schrier SL. Pathobiology of thalassemic erythrocytes. Curr Opin Hematol 1997;4:75-8.
21. Shinar E, Rachmilewitz EA. Haemoglobinopathies and red cell membrane function. Baillieres Clin Haematol 1993;6:357-69.
22. Grinberg LN, Rachmilewitz EA. Oxidative stress in β-thalassemic red blood cells and potential use of antioxidants. In: Beuzard Y, Lubin B, Rosa J, eds. Sickle cell disease and thalassaemia: new trends in therapy. London: Colloque INSERM/John Libby Eurotext, 1995:519-24.
23. Sorensen S, Rubin E, Polster H, Mohandas N, Schrier S. The role of membrane skeletal-associated alpha-globin in the pathophysiology of beta-thalassemia. Blood 1990;75:1333-6.
24. Shalev O, Repka T, Goldfarb A, et al. Deferiprone (Ll) chelates pathologic iron deposits from membranes of intact thalassemic and sickle RBC both in vitro and in vivo. Blood 1995;86:2008-13.
25. Rioja L, Girot R, Garabedian M, Cournot-Witmer G. Bone disease in children with homozygous bcta-thalassemia. Bone Miner 1990;8:69-86.
26. Orvieto R, Leichter I, Rachmilewitz EA, Margulies JY. Bone density, mineral content, and cortical index in patients with thalassemia major and the correlation to their bone fractures, blood transfusions, and treatment with desferrioxamine. Calcif Tissue Int 1992;50:397-9.
27. Gratwick GM, Bullough PG, Bohne WHO, Markenson AL, Peterson CM. Thalassemia osteoarthropathy. Ann Intern Med 1978;88:494-501.
28. Thein SL. β-Thalassaemia. Baillieres Clin Haematol 1993;6:151-75.
29. Weatherall DJ, Clegg JB. The thalassaemia syndromes. 4th ed. Oxford, England: Blackwell Scientific (in press).
30. Thein SL, Sampietro M, Rohde K, et al. Detection of a major gene for heterocellular hereditary persistence of fetal hemoglobin after accounting for genetic modifiers. Am J Hum Genet 1994;54:214-28.
31. Dover GJ, Smith KD, Chang YC, et al. Fetal hemoglobin levels in sickle cell disease and normal individuals are partially controlled by an X-linked gene located at Xp22.2. Blood 1992;80:816-24.
32. Chang YC, Smith KD, Moore RD, Serjeant GR, Dover GJ. An analysis of fetal hemoglobin variation in sickle cell disease: the relative contributions of the X-linked factor, β-globin haplotypes, α-globin gene number, gender, and age. Blood 1995;85:1111-7.
33. Thein SL, Hesketh C, Taylor P, et al. Molecular basis for dominantly inherited inclusion body β thalassemia. Proc Natl Acad Sci U S A 1990; 87:3924-8.
34. Camaschella C, Cappellini MD. Thalassemia intermedia. Haematologica 1995;80:58-68.
35. Cao A. Diagnosis of β-thalassemia intermedia at presentation. In: Fucharoen S, Rowley PT, Paul NW, eds. Thalassemia: pathophysiology and management. Part B. Vol. 23 of Birth defects: original article series. New York: Alan R. Liss, 1988:219-26.
36. Rund D, Oron-Karni V, Filon D, Goldfarb A, Rachmilewitz E, Oppenheim A. Genetic analysis of β-thalassemia intermedia in Israel: diversity of mechanisms and unpredictability of phenotype. Am J Hematol 1997;54: 16-22.
37. Ho PJ, Hall GW, Luo LY, Weatherall DJ, Thein SL. Beta thalassaemia intermedia: is it possible consistently to predict phenotype from genotype? Br J Haematol 1998;100:70-8.
38. Huisman THJ, Carver MFH, Baysal E. A syllabus of thalassemia mutations. Augusta, Ga.: Sickle Cell Anemia Foundation, 1997:309.
39. Weatherall DJ. Hemoglobin E β-thalassemia: an increasingly common disease with some diagnostic pitfalls. J Pediatr 1998;132:765-7.
40. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-61. [Erratum, Blood 1997;89:2621.]
41. Pippard MJ, Callender ST, Warner GT, Weatherall DJ. Iron absorption and loading in beta-thalassaemia intermedia. Lancet 1979;2:819-21.
42. Pootrakul P, Kitcharoen K, Yansukon P, et al. The effect of erythroid hyperplasia on iron balance. Blood 1988;71:1124-9.
43. Risdon RA, Flynn DM, Barry M. The relation between liver iron concentration and liver damage in transfusional iron overload in thalassaemia and the effect of chelation therapy. Gut 1973;14:421.
44. Hershko C, Weatherall DJ. Iron-chelating therapy. Crit Rev Clin Lab Sci 1988;26:303-45.
45. Hershko C, Konijn AM, Link G. Iron chelators for thalassaemia. Br J Haematol 1998;101:399-406.
46. Parkes JG, Hussain RA, Olivieri NF, Templeton DM. Effects of iron loading on uptake, speciation, and chelation of iron in cultured myocardial cells. J Lab Clin Med 1993;122:36-47.
47. Buja LM, Roberts W. Iron in the heart: etiology and clinical significance. Am J Med 1971;51:209-21.
48. Wolfe L, Olivieri N, Sallan D, et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 1985;312:1600-3.
49. Kremastinos DT, Tiniakos G, Theodorakis GN, Katritsis DG, Toutouzas PK. Myocarditis in β-thalassemia major: a cause of heart failure. Circulation 1995;91:66-71.
50. Aessopos A, Stamatelos G, Skoumas V, Vassilopoulos G, Mantzourani M, Loukopoulos D. Pulmonary hypertension and right heart failure in patients with β-thalassemia intermedia. Chest 1995;107:50-3.
51. Du ZD, Roguin N, Milgram E, Saab K, Koren A. Pulmonary hypertension in patients with thalassemia major. Am Heart J 1997;134:532-7.
52. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-73.
53. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 1994;331: 574-8.
54. Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet 1989;2:27-30.
55. Iancu TC, Neustein HB, Landing BH. The liver in thalassaemia major: ultrastructural observations. In: Iron metabolism: Ciba Symposium 51. Amsterdam: Elsevier, 1977:293-309.
56. Thakerngpol K, Fucharoen S, Boonyaphipat P, et al. Liver injury due to iron overload in thalassemia: histopathologic and ultrastructural studies. Biometals 1996;9:177-83.
57. Witzleben CL, Wyatt JP. The effect of long survival on the pathology of thalassaemia major. J Pathol Bacteriol 1961;82:1-12.
58. Jean G, Terzoli S, Mauri R, et al. Cirrhosis associated with multiple transfusions in thalassaemia. Arch Dis Child 1984;59:67-70.
59. Maharaj B, Maharaj RJ, Leary WP, et al. Sampling variability and its influence on the diagnostic yield of the percutaneous needle biopsy of the liver. Lancet 1986;1:523-5.
60. Cartwright GE, Edwards CQ, Kravitz K, et al. Hereditary hemochromatosis: phenotypic expression of the disease. N Engl J Med 1979;301: 175-9.
61. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-79.
62. Parkes JG, Randell EW, Olivieri NF, Templeton DM. Modulation by iron loading and chelation of the uptake of non-transferrin-bound iron by human liver cells. Biochim Biophys Acta 1995;1243:373-80.
63. Italian Working Group on Endocrine Complications in Non-endocrine Diseases. Multicentre study on prevalence of endocrine complications in thalassaemia major. Clin Endocrinol (Oxf) 1995;42:581-6.
64. Cavallo-Perin P, Pacini G, Cerutti F, et al. Insulin resistance and hyperinsulinemia in homozygous β-thalassemia. Metabolism 1995;44:281-6.
65. Gullo L, Corcioni E, Brancati C, Bria M, Pezzilli R, Sprovieri G. Morphologic and functional evaluation of the exocrine pancreas in β-thalassemia major. Pancreas 1993;8:176-80.
66. Magro S, Puzzonia P, Consarino C, et al. Hypothyroidism in patients with thalassemia syndromes. Acta Haematol 1990;84:72-5.
67. Sklar CA, Lew LQ, Yoon DJ, David R. Adrenal function in thalassemia major following long-term treatment with multiple transfusions and chelation therapy: evidence for dissociation of cortisol and adrenal androgen secretion. Am J Dis Child 1987;141:327-30.
68. Bacalo A, Kivity S, Heno N, Greif Z, Greif J, Topilsky M. Blood transfusion and lung function in children with thalassemia major. Chest 1992; 101:362-70.
69. Factor JM, Pottipati SR, Rappaport I, Rosner IK, Lesser ML, Giardina PJ. Pulmonary function abnormalities in thalassemia major and the role of iron overload. Am J Respir Crit Care Med 1994;149:1570-4.
70. Tai DYH, Wang YT, Lou J, Wang WY, Mak KH, Cheng HK. Lungs in thalassaemia major patients receiving regular transfusion. Eur Respir J 1996;9:1389-94.
71. Anapliotou MLG, Kastanias IT, Psara P, Evangelou EA, Liparaki M, Dimitriou P. The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches. Clin Endocrinol (Oxf) 1995;42:279-87.
72. Filosa A, Di Maio S, Vocca S, Saviano A, Esposito G, Pagano L. Longitudinal monitoring of bone mineral density in thalassemic patients: genetic structure and osteoporosis. Acta Paediatr 1997;86:342-6.
73. Olivieri NF. Thalassaemia: clinical management. Baillieres Clin Haematol 1998;11:147-62.
74. Cao A, Galanello R, Rosatelli MC. Prenatal diagnosis and screening of the haemoglobinopathies. Baillieres Clin Haematol 1998;11:215-38.
75. Fosburg MT, Nathan DG. Treatment of Cooley's anemia. Blood 1990; 76:435-44.
76. Cazzola M, Bornga-Pignatti C, Locatelli F, Ponchio L, Beguin Y, De Stefano P. A moderate transfusion regimen may reduce iron loading in β-thalassemia major without producing excessive expansion of erythropoiesis. Transfusion 1997;37:135-40.
77. Barry M, Flynn DM, Letsky EA, Risdon RA. Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress. BMJ 1974;2:16-20.
78. Bronspiegel-Weintrob N, Olivieri NF, Tyler B, Andrews DF, Freedman MH, Holland FJ. Effect of age at the start of iron chelation therapy on gonadal function in β-thalassemia major. N Engl J Med 1990;323:713-9.
79. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996;95:26-36.
80. Porter JB. A risk-benefit assessment of iron-chelation therapy. Drug Saf 1997;17:407-21.
81. Brittenham GM, Cohen AR, McLaren CE, et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 1993;42:81-5.
82. Angelucci E, Giardini C, Brittenham GM, Lucarelli G. Hepatic iron concentration and body iron stores determined by quantitative phlebotomy in patients cured of thalassemia major by bone marrow transplantation. Blood 1997;90:Suppl 1:265a. abstract.
83. Olynyk JK, O'Neill R, Britton RS, Bacon BR. Determination of hepatic iron concentration in fresh and paraffin-embedded tissue: diagnostic implications. Gastroenterology 1994;106:674-7.
84. Brittenham GM, Farrell DE, Harris JW, et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med 1982;307:1671-5.
85. Angelucci E, Giovagnoni A, Valeri G, et al. Limitations of magnetic resonance imaging in measurement of hepatic iron. Blood 1997;90:4736-42.
86. Giardini C. Treatment of β-thalassemia. Curr Opin Hematol 1997;4: 79-87.
87. Lucarelli G, Giardini C, Angelucci E. Bone marrow transplantation in thalassemia. In: Winter JN, ed. Blood stem cell transplantation. Boston: Kluwer Academic, 1997:305-15.
88. Issaragrisil S, Visuthisakchai S, Suvattt V, et al. Transplantation of cord-blood stem cells into a patient with severe thalassemia. N Engl J Med 1995;332:367-9.
89. Contu L, La Nasa G, Arras M, et al. Successful unrelated bone marrow transplantation in β-thalassemia. Bone Marrow Transplant 1994;13:329-31.
90. Westgren M, Ringden O, Eik-Nes S, et al. Lack of evidence of permanent engraftment after in utero fetal stem cell transplantation in congenital hemoglobinopathies. Transplantation 1996;61:1176-9.
91. Olivieri NF, Brittenham GM, Matsui D, et al. Iron chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995;332:918-22.
92. Hoffbrand AV, al-Refaie F, Davis B, et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998; 91:295-300.
93. Olivieri NF, Brittenham GM, McLaren CE, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone in patients with thalassemia major. N Engl J Med 1998;339:417-23.
94. Hoffbrand AV. Oral iron chelation. Semin Hematol 1996;33:1-8.
95. Carthew P, Smith AG, Hider RC, Dorman B, Edwards RE, Francis JE. Potentiation of iron accumulation in cardiac myocytes during the treatment of iron overload in gerbils with the hydroxypyridinone iron chelator CP94. Biometals 1994;7:267-71.
96. Wong A, Alder V, Robertson D, et al. Liver iron depletion and toxicity of the iron chelator deferiprone (Ll, CP20) in the guinea pig. Biometals 1997;10:247-56.
97. Nathan DG. An orally active iron chelator. N Engl J Med 1995;332: 953-4. [Erratum, N Engl J Med 1995;332:1315.]
98. Olivieri NF, Nisbet-Brown E, Srichairatanakool S, et al. Studies of iron excretion and non-transferrin-bound plasma iron (NTBPI) following a single infusion of hydroxyethyl starch-deferoxamine (HES-DFO): a new approach to iron chelation therapy. Blood 1996;88:Suppl 1:310a. abstract.
99. Borgna-Pignatti C, Cohen AR. Evaluation of a new method of administration of the iron chelating agent deferoxamine. J Pediatr 1997;130:86-8.
100. Porter JB, Alberti D, Hassan I, et al. Subcutaneous depot desferrioxamine (CGH 749B): relationship of pharmacokinetics to efficacy and drug metabolism. Blood 1997;90:Suppl 1:265a. abstract.
101. Olivieri NF. Reactivation of fetal hemoglobin in patients with β-thalassemia. Semin Hematol 1996;33:24-42.
102. + thalassemia. N Engl J Med 1982;307:1469-75.
103. Arruda VR, Lima CSP, Saad STO, Costa FF. Successful use of hydroxyurea in β-thalassemia major. N Engl J Med 1997;336:964.
104. Rigano P, Manfré L, La Galla R, et al. Clinical and hematologic response to hydroxyurea in a patient with Hb Lepore/β-thalassemia. Hemoglobin 1997;21:219-26.
105. Perrine SP, Ginder CD, Faller DV, et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the β-globin disorders. N Engl J Med 1993;328:81-6.
106. Olivieri NF, Rees DC, Ginder GD, et al. Treatment of thalassemia major with phenylbutyrate and hydroxyurea. Lancet 1997;350:491-2.
107. Rodgers GP, Rachmilewitz EA. Novel treatment options in the severe β-globin disorders. Br J Haematol 1995;91:263-8.
108. Saxon BR, Rees D, Olivieri NF. Regression of extramedullary haemopoiesis and augmentation of fetal haemoglobin concentration during hydroxyurea therapy in β thalassaemia. Br J Haematol 1998;101:416-9.
109. Sher GD, Ginder GD, Little JA, Wang SY, Dover G, Olivieri NF. Extended therapy with intravenous arginine butyrate in patients with β-hemoglobinopathies. N Engl J Med 1995;332:1606-10.
110. Atweh GF, Sutton M, Nassif I, et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood 1999;93: 1790-7.
111. Collins AF, Pearson HA, Giardina P, McDonagh KT, Brusilow SW, Dover GJ. Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood 1995;85:43-9.
112. Cappellini MD, Graziadei G, Ciceri L, et al. Phase II open study of oral isobutyramide in patients with thalassemia intermedia. Blood 1996; 88:Suppl 1:311a. abstract.
113. Constantoulakis P, Josephson B, Mangahas L, et al. Locus control region-Aγ transgenic mice: a new model for studying the induction of fetal hemoglobin in the adult. Blood 1991;77:1326-33.
114. Stamatoyannopoulos JA, Nienhuis AW. Therapeutic approaches to hemoglobin switching in treatment of hemoglobinopathies. Ann Rev Med 1992;43:497-521.
115. McDonagh KT, Dover GJ, Donahue RE, et al. Hydroxyurea-induced HbF production in anemic primates: augmentation by erythropoietin, hematopoietic growth factors, and sodium butyrate. Exp Hematol 1992; 20:1156-64.
116. Pace B, Li Q, Peterson K, Stamatoyannopoulos G. α-Amino butyric acid cannot reactivate the silenced gamma gene of the beta locus YAC transgenic mouse. Blood 1994;84:4344-53.
117. Kitsberg D, Selig S, Keshet I, Cedar H. Replication structure of the human β-globin gene domain. Nature 1993;366:588-90.
118. Verma IM, Somia N. Gene therapy - promises, problems and prospects. Nature 1997;389:239-42.
119. Higgs DR, Sharpe JA, Wood WG. Understanding α-globin gene expression: a step towards effective gene therapy. Semin Hematol 1998;35: 93-104.
120. s-globin gene by gene targeting. Proc Natl Acad Sci U S A 1991;88:4294-8.